The Current Landscape
As of 2026, the GLP-1 space has evolved from a single approved medication (Byetta, 2005) to a robust class that includes once-weekly injectables, oral options, dual agonists, and triple agonists in late-stage trials. Average weight loss has progressed from approximately 5% with liraglutide to over 20% with tirzepatide and potentially 25%+ with retatrutide. The pace of innovation is accelerating.
Next-Generation Formulations
Monthly Injectables
Several companies are developing once-monthly versions of semaglutide and other GLP-1 agents. Moving from weekly to monthly dosing could meaningfully improve adherence, particularly for patients who find the weekly injection schedule burdensome.
Implantable Devices
Researchers are exploring implantable devices that deliver a continuous low dose of a GLP-1 agonist over months or even years — eliminating injections entirely and ensuring consistent drug levels. This technology remains in early research stages.
Oral Non-Peptide Agents
Orforglipron (Eli Lilly) and several other companies' non-peptide oral GLP-1 agonists represent the most near-term access expansion. A pill that works as well as Wegovy, taken once daily without fasting restrictions, could dramatically expand the treatable population.
Combination Approaches
Beyond adding a second or third receptor target, researchers are exploring combinations of GLP-1 agonists with amylin analogues (CagriSema), GIP antagonists, leptin sensitizers, and other metabolic hormones. Each combination targets a different aspect of the complex hormonal regulation of body weight.
Accessibility and Cost
The most transformative near-term development in the GLP-1 space may not be a new molecule — it may be cost reduction through competition, patent expirations, and the introduction of biosimilar semaglutide, expected to begin entering the market in the late 2020s. Lower prices would dramatically expand access to a class of medications that could benefit hundreds of millions of people worldwide.
The decade from 2025 to 2035 may be remembered as the period when obesity shifted from being treated primarily as a behavioral condition to being recognized and treated as a complex, chronic, and highly treatable hormonal disease.